Cagrilintide dosing chart (mg to units)
Cagrilintide is described in PinPoint as a long-acting amylin analog, even though the library organizes it within the GLP-1 category. Its Investigational status accompanies a 5 mg vial reference. The conversion rows below are fractions of that vial, expressed in mg.
Vial concentration
Water mL is treated as final solution mL in these columns.
| Vial contents | 1 mL water | 2 mL water | 3 mL water |
|---|---|---|---|
| 5 mg | 5 mg/mL20 U-100 units per mg | 2.5 mg/mL40 U-100 units per mg | 1.6667 mg/mL60 U-100 units per mg |
Vial source: PinPoint/Data/CompoundLibrary.swift, line 675, the Cagrilintide entry. One documented amount is available.
Amount to units
Example amounts (arithmetic only, not doses).
| Amount (mg) | 5 mg + 1 mL | 5 mg + 2 mL | 5 mg + 3 mL |
|---|---|---|---|
| 0.1 mg | 2 units | 4 units | 6 units |
| 0.25 mg | 5 units | 10 units | 15 units |
| 0.5 mg | 10 units | 20 units | 30 units |
| 1 mg | 20 units | 40 units | 60 units |
| 2.5 mg | 50 units | 100 units | 150 unitsover one syringe |
Cited amounts
| Amount (mg) and source context | Frequency as stated | Route as stated | 5 mg + 1 mL | 5 mg + 2 mL | 5 mg + 3 mL | Source |
|---|---|---|---|---|---|---|
| 0.3 mgAdult phase 2 study group; 26 weeks including up to 6 weeks of escalation. | Once weekly | Subcutaneous | 6 units | 12 units | 18 units | Cagrilintide phase 2 study, Lancet (2021)Peer-reviewed studyRetrieved 2026-10-05 |
| 0.6 mgAdult phase 2 study group; 26 weeks including up to 6 weeks of escalation. | Once weekly | Subcutaneous | 12 units | 24 units | 36 units | Cagrilintide phase 2 study, Lancet (2021)Peer-reviewed studyRetrieved 2026-10-05 |
| 1.2 mgAdult phase 2 study group; 26 weeks including up to 6 weeks of escalation. | Once weekly | Subcutaneous | 24 units | 48 units | 72 units | Cagrilintide phase 2 study, Lancet (2021)Peer-reviewed studyRetrieved 2026-10-05 |
| 2.4 mgAdult phase 2 study group; 26 weeks including up to 6 weeks of escalation. | Once weekly | Subcutaneous | 48 units | 96 units | 144 unitsover one syringe | Cagrilintide phase 2 study, Lancet (2021)Peer-reviewed studyRetrieved 2026-10-05 |
| 4.5 mgAdult phase 2 study group; 26 weeks including up to 6 weeks of escalation. | Once weekly | Subcutaneous | 90 units | 180 unitsover one syringe | 270 unitsover one syringe | Cagrilintide phase 2 study, Lancet (2021)Peer-reviewed studyRetrieved 2026-10-05 |
How to read this chart
Find the concentration column. Divide the amount by that concentration. Multiply the mL value by 100 for U-100 units. Match the amount units before dividing.
units = amount ÷ (vial mg ÷ water mL) × 100
Amount and volume
One mg equals 1,000 mcg; 100 U-100 units equals 1 mL. Concentration connects amount to volume. Read the full conversion guide.
Why category and description differ
A library category is an organizational field, while the compound description carries the more specific identity. For cagrilintide, the description points to amylin-analog study context rather than identifying it as a GLP-1 receptor agonist. PinPoint's entry cites peer-reviewed clinical literature and keeps the Investigational research tag visible in its data. This distinction matters when comparing neighboring records in the chart directory: sharing a category does not make their model inputs, documented vial amounts, or pharmacological descriptions interchangeable.
The weekly timescale in PinPoint
Cagrilintide's modeled elimination half-life is 168 hours. Its peak-time parameter is 24 hours, and the base bioavailability field is 0.75, equivalent to 75%. Together, these values give the app separate references for a week-scale decline and a day-scale absorption peak. The frequency text is Every 7 days. A series of dated entries can therefore be viewed against a long model window rather than compressed into a few hours. The record's long-acting description is reflected in that stored timescale, not in the number of syringe units.
The recorded route and the example ladder
The app lists subcutaneous for cagrilintide and uses a compounded vial form. No preset dose values are stored for this entry, so the amount table works directly from the documented container total. Its rows are 0.1, 0.25, 0.5, 1, and 2.5 mg. These correspond to one fiftieth, one twentieth, one tenth, one fifth, and one half of 5 mg. This sequence lets a reader compare the same fraction across different liquid volumes without confusing it with the preset lists on the other GLP-1 pages.
A 5 mg catalog vial in the table
The source for cagrilintide's vial amount is a supplier catalog describing 5 mg of lyophilized material. At a final volume of 2 mL, that amount gives a concentration of 2.5 mg per mL. The 1 mg example occupies two fifths of a milliliter, or 40 U-100 units. Moving to the 1 mL column halves that volume to 0.2 mL; moving to 3 mL raises it to 0.6 mL. The row remains a 1 mg amount through all three comparisons.
Questions about the conversion
What concentration is Cagrilintide at 5 mg in 1 mL?
5 mg divided by 1 mL is 5 mg per mL. That volume spans 100 U-100 syringe units.
How does 2 mL change the concentration of this Cagrilintide vial?
5 mg divided by 2 mL is 2.5 mg per mL, half the concentration in the 1 mL column.
What does the 3 mL column mean for Cagrilintide?
5 mg divided by 3 mL is approximately 1.6667 mg per mL. The full 3 mL volume corresponds to 300 U-100 units.
How many units is 0.5 mg of Cagrilintide from this vial in 2 mL?
0.5 mg divided by 2.5 mg per mL is 0.2 mL, or 20 U-100 units.
How many units is the 0.3 mg cited amount of Cagrilintide from a 5 mg vial in 2 mL?
The arithmetic is 0.3 mg ÷ 2.5 mg/mL × 100 = 12 U-100 units (0.12 mL). The amount is cited in Cagrilintide phase 2 study, Lancet (2021). Adult phase 2 study group; 26 weeks including up to 6 weeks of escalation.
Track your calculations in the app
PinPoint for iOS brings vial setup, unit conversion, dose logs, site rotation, and protocol tracking together. Enter vial size and water volume for concentration and syringe units, then log injections with compound, dose, site, and pain level.
Get PinPoint on the App Store